Celularity Appoints Richard J. Berman to Its Board of Directors

FLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative and cellular medicine company developing allogeneic placental cell therapies and advanced biomaterial products, today announced the appointment of Richard J. Berman to its Board of Directors. Mr. Berman is a seasoned public company executive with a career spanning more than 40 years of venture capital, senior management, and mergers and acquisitions experience. Over the past five years, he has served as a director and/or board member of more than a dozen public and private companies, six of which have achieved market capitalizations in excess of $1 billion. Previously, Mr. Berman worked at Goldman Sachs and was Senior Vice President of Bankers Trust Company, where he founded the M&A Leveraged Buyout businesses. He has also advised on mergers and acquisitions transactions valued at over $4 billion, executing over 300 transactions.

“I am pleased to welcome Richard Berman to Celularity’s Board of Directors, where he brings unique experience and leadership in leading public companies and helping them build and execute growth plans,” said Robert J. Hariri, MD, Ph.D., founder, chairman and chief executive officer of Celularity. Mr. Berman commented on his new role, “I am pleased to join Celularity at this pivotal time and look forward to working with Dr. Hariri and his team as we execute the company’s focused and disciplined growth plan.”

About Celularity

Celularity Inc. (NASDAQ: CELU) is an innovative regenerative and cellular medicine company that develops and commercializes advanced biomaterial products and allogeneic, cryopreserved placenta-derived cell therapies, all derived from the postpartum placenta. Celularity’s distinguishing feature is its therapeutic programs targeting diseases of aging, including degenerative diseases, cancers and immune disorders, using mesenchymal stromal cells (MLASC), CAR-engineered T cells (CAR T cells), and genetically engineered and unengineered natural killer (NK) cells. Celularity’s unique approach, leveraging the biology of the placenta and its ready availability, is paving the way for therapeutic solutions that address the significant unmet need for unique biology and ready availability, and can develop therapeutic solutions that address the need for effective, accessible and affordable therapies.

Contact for investors:
Carlos Ramirez
Senior Vice President, Celularity Inc.
[email protected]

Media contact:
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
[email protected] / [email protected]